Zimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery
Rhea-AI Summary
Zimmer Biomet (NYSE: ZBH) and OneStep announced an exclusive collaboration to integrate OneStep's clinically validated mobility intelligence into Zimmer Biomet's mymobility Care Management Platform for joint replacement patients, effective Dec 16, 2025.
The integration will feed smartphone-based gait and functional mobility analytics (iPhone and Android) directly into mymobility to support remote assessment, patient engagement, and clinician-tailored rehabilitation. OneStep processes more than one million gait cycles every day, providing a large real-world mobility dataset to quantify recovery trends and functional outcomes.
Positive
- Exclusive collaboration to integrate OneStep into mymobility
- One million+ gait cycles/day powering mobility intelligence
- Smartphone-based gait analytics available on iPhone and Android
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ZBH was up 0.92% while key peers were mixed: SNN and PHG each down 0.34%, PODD down 1.55%, DXCM down 2.51%, and STE up 0.66%, pointing to a stock-specific move rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Robotics clearance | Positive | -0.7% | U.S. FDA 510(k) clearance for enhanced ROSA Knee with OptimiZe features. |
| Nov 07 | Conference appearance | Neutral | -0.0% | Management presentation planned at Jefferies Global Healthcare Conference. |
| Nov 05 | Q3 2025 earnings | Positive | -15.2% | Q3 net sales $2.001B with EPS growth and portfolio-expanding acquisitions. |
| Oct 28 | Breakthrough designation | Positive | -1.9% | FDA Breakthrough Device Designation for iodine-treated total hip system. |
| Oct 21 | Product showcase | Positive | -0.1% | Showcased robotics and musculoskeletal innovations at AAHKS meeting. |
Recent history shows a pattern of negative price reactions to otherwise positive product and regulatory news, including earnings and FDA-related milestones.
Over the last few months, Zimmer Biomet reported several notable developments. On Oct 21, 2025, it highlighted robotics and musculoskeletal innovations at the AAHKS meeting, followed by an Oct 28, 2025 FDA Breakthrough Device Designation for an iodine-treated hip system. Third-quarter 2025 results on Nov 5, 2025 showed net sales of $2.001B and adjusted diluted EPS of $1.90, alongside acquisitions to expand robotics and extremities. On Nov 14, 2025, the company received U.S. FDA 510(k) clearance for an enhanced ROSA Knee system. The current digital-mobility collaboration extends this tech-enabled care strategy into recovery monitoring.
Market Pulse Summary
This announcement extends Zimmer Biomet’s connected-care strategy by integrating OneStep’s mobility intelligence into the mymobility platform, aiming to give surgeons and patients continuous, smartphone-based recovery data. It builds on recent advances in robotics and digital tools, such as enhanced ROSA Knee and prior FDA designations. Investors may watch adoption of the mymobility platform, clinical impact of monitoring more than 1,000,000 gait cycles daily, and how these digital capabilities complement core implant and robotics offerings.
Key Terms
gait medical
telehealth technical
AI-generated analysis. Not financial advice.
OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility® Care Management Platform to Further Enhance Recovery Monitoring
WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering the orthopedic industry's most comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery and enable patients to play an active role in their recovery.
The collaboration will use OneStep's gait and mobility analytics that are captured on both iPhone® and Android™ smartphones and integrate the data directly into Zimmer Biomet's mymobility® Care Management Platform for orthopedic surgery patients. Users of mymobility have access to daily, objective insights across their joint replacement journey, from surgical preparation through recovery using only their smartphone. The integration enables remote assessment of gait and functional mobility powered by OneStep's clinically validated technology, delivered seamlessly through the mymobility app.
"This partnership represents a significant step forward in continuing to connect the dots between surgical innovation, patient engagement and functional outcomes," said Robert Kraal, vice president and general manager of Connected Health at Zimmer Biomet. "By incorporating OneStep's advanced analytics into mymobility, we can further personalize and strengthen our ability to measure what matters most — how patients move in their daily lives — while keeping data capture effortless for patients and low-burden for clinicians."
The integration supports Zimmer Biomet's broader connected care strategy, which links technology, data and digital tools across the patient journey. Powered by analysis of more than one million gait cycles every day, OneStep's mobility intelligence provides one of the world's largest real-world mobility datasets. By embedding OneStep's mobility intelligence, Zimmer Biomet enhances its ability to monitor recovery trends, quantify function and support clinicians in tailoring rehabilitation programs with objective, real-world insights.
"Zimmer Biomet has set the standard for digital, connected orthopedic care, and our mobility intelligence is perfectly aligned to their vision," said Tomer Shussman, CEO of OneStep. "Together, we're transforming gait and mobility into a vital sign, empowering patients and providers with clinically meaningful data intended to improve outcomes."1
The mymobility Care Management Platform provides a guided orthopedic patient experience, including education, surveys, check-ins, messaging, video-guided post-operative exercises, gait and mobility metrics, analytics and telehealth applications — all with automation, data and insights for surgeons to monitor their patients' recovery process.
iPhone is a registered trademark of Apple, Inc. Android is a trademark of Google LLC.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
About OneStep
OneStep is an FDA-listed, digital care platform that transforms any smartphone into a continuous movement sensor, capturing gait, balance, and mobility data to assess risk, track progress, and personalize care. From fall prevention to orthopedic recovery, cognitive decline to chronic condition monitoring, OneStep brings mobility insights out of the lab and into real life. Because when we can measure how people move, we can change how they're cared for." Learn more at www.onestep.co.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the
Contacts: Media Troy Kirkpatrick 614-284-1926 troy.kirkpatrick@zimmerbiomet.com Kirsten Fallon 781-779-5561 | Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com Zach Weiner 908-591-6955 |
____________________________
1 Redfern RE, Khan ST, Archibeck MJ, Anderson MB, Piuzzi NS. Establishing Minimal Clinically Important Differences and Substantial Clinical Benefit Thresholds for Various Objective Gait Metrics After Total Knee Arthroplasty. International Society for Technology in Arthroplasty (ISTA) Annual Congress; September 2025;
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-onestep-collaborate-to-provide-enhanced-mobility-data-to-patients-and-surgeons-to-help-improve-joint-procedure-recovery-302642724.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
What did Zimmer Biomet announce about OneStep on December 16, 2025?
How will the OneStep integration affect mymobility users (ZBH)?
What devices does OneStep's mobility technology support for ZBH patients?
How large is the mobility dataset OneStep brings to Zimmer Biomet?
Will Zimmer Biomet clinicians be able to tailor rehabilitation using the new data (ZBH)?
What stages of the joint replacement journey does mymobility cover after the integration?
